<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002178</url>
  </required_header>
  <id_info>
    <org_study_id>229J</org_study_id>
    <secondary_id>NR15539</secondary_id>
    <nct_id>NCT00002178</nct_id>
  </id_info>
  <brief_title>A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients</brief_title>
  <official_title>A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of
      detection (&lt; 400 copies/ml) at week 16 and 24 of study therapy. To determine the absolute
      change in plasma HIV-1 RNA and in absolute CD4 cell count during the 24 weeks of study
      treatment. To collect safety data on the treatment regimens. To determine the percentage of
      patients without SQV soft gel capsules resistance-associated mutations at week 24.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive 1 of 3 study regimens: Group A - Saquinavir (SQV) soft gel
      capsules (sgc) plus 2 reverse transcriptase inhibitors (RTIs), Group B - SQV sgc plus
      delavirdine plus RTI, and Group C - SQV sgc plus nelfinavir plus RTI (or SQV sgc plus
      ritonavir plus 2 RTIs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>375</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delavirdine mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  HIV RNA &gt;= 5000 copies/ml by Amplicor assay.

          -  Signed, informed consent from parent or legal guardian for patients less than 18 years
             old.

        Previous treatment with antiretrovirals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr Charles Farthing</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cadman J. Roche brings new formulation of saquinavir to FDA. Food and Drug Administration. GMHC Treat Issues. 1997 Apr-May;11(4/5):8.</citation>
    <PMID>11364377</PMID>
  </reference>
  <verification_date>August 1997</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Dosage Forms</keyword>
  <keyword>Saquinavir</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Delavirdine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

